ABCL
Price
$12.18
Change
+$1.06 (+9.53%)
Updated
Nov 3 closing price
Capitalization
3.95B
6 days until earnings call
Intraday BUY SELL Signals
NTLA
Price
$11.86
Change
+$0.20 (+1.72%)
Updated
Nov 3 closing price
Capitalization
1.66B
2 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABCL vs NTLA

ABCL vs NTLA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ABCL vs. NTLA commentary
Nov 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABCL is a Buy and NTLA is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ABCL with price predictions
Nov 02, 2026

ABCL in +12.91% Uptrend, rising for three consecutive days on October 28, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ABCL advanced for three days, in 207 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis
Bearish Trend Analysis

The 10-day RSI Indicator for ABCL moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 27 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 53 cases where ABCL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABCL as a result. In 73 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for ABCL turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 33 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.

ABCL moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ABCL crossed bearishly below the 50-day moving average on November 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABCL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

ABCL broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ABCL entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.405) is normal, around the industry mean (3.104). P/E Ratio (-22.556) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (53.191) is also within normal values, averaging (439.647).

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ABCL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABCL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for NTLA with price predictions
Nov 03, 2026

Aroon Indicator for NTLA shows an upward move is likely

NTLA's Aroon Indicator triggered a bullish signal on October 14, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 128 similar instances where the Aroon Indicator showed a similar pattern. In 107 of the 128 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on NTLA as a result. In 77 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.

The Moving Average Convergence Divergence (MACD) for NTLA just turned positive on October 28, 2026. Looking at past instances where NTLA's MACD turned positive, the stock continued to rise in 32 of 46 cases over the following month. The odds of a continued upward trend are 70%.

Following a +18.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTLA advanced for three days, in 202 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 51 cases where NTLA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

NTLA moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for NTLA crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 18 of 21 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTLA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

NTLA broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.284) is normal, around the industry mean (3.051). P/E Ratio (-3.551) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (23.095) is also within normal values, averaging (439.647).

The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. NTLA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NTLA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
ABCL vs NTLA: Fundamental Ratings
ABCL
NTLA
OUTLOOK RATING
1..100
1416
VALUATION
overvalued / fair valued / undervalued
1..100
10
Undervalued
38
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9498
PRICE GROWTH RATING
1..100
3459
P/E GROWTH RATING
1..100
9758
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ABCL's Valuation (10) in the null industry is in the same range as NTLA (38) in the Biotechnology industry. This means that ABCL’s stock grew similarly to NTLA’s over the last 12 months.

ABCL's Profit vs Risk Rating (100) in the null industry is in the same range as NTLA (100) in the Biotechnology industry. This means that ABCL’s stock grew similarly to NTLA’s over the last 12 months.

ABCL's SMR Rating (94) in the null industry is in the same range as NTLA (98) in the Biotechnology industry. This means that ABCL’s stock grew similarly to NTLA’s over the last 12 months.

ABCL's Price Growth Rating (34) in the null industry is in the same range as NTLA (59) in the Biotechnology industry. This means that ABCL’s stock grew similarly to NTLA’s over the last 12 months.

NTLA's P/E Growth Rating (58) in the Biotechnology industry is somewhat better than the same rating for ABCL (97) in the null industry. This means that NTLA’s stock grew somewhat faster than ABCL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABCLNTLA
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 1 day ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 1 day ago
70%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 7 days ago
81%
Bullish Trend 7 days ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 1 day ago
84%
COMPARISON
Comparison
Nov 04, 2026
Stock price -- (ABCL: $12.18 vs. NTLA: $11.86)
Brand notoriety: ABCL and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABCL: 48% vs. NTLA: 59%
Market capitalization -- ABCL: $3.95B vs. NTLA: $1.66B
ABCL [@Biotechnology] is valued at $3.95B. NTLA’s [@Biotechnology] market capitalization is $1.66B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $134.53B. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABCL’s FA Score shows that 1 FA rating(s) are green while NTLA’s FA Score has 0 green FA rating(s).

  • ABCL’s FA Score: 1 green, 4 red.
  • NTLA’s FA Score: 0 green, 5 red.
According to our system of comparison, ABCL is a better buy in the long-term than NTLA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABCL’s TA Score shows that 1 TA indicator(s) are bullish while NTLA’s TA Score has 4 bullish TA indicator(s).

  • ABCL’s TA Score: 1 bullish, 9 bearish.
  • NTLA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than ABCL.

Price Growth

ABCL (@Biotechnology) experienced а -5.07% price change this week, while NTLA (@Biotechnology) price change was -3.42% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.06%. For the same industry, the average monthly price growth was -12.02%, and the average quarterly price growth was -17.00%.

Reported Earning Dates

ABCL is expected to report earnings on Nov 09, 2026.

NTLA is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-2.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ABCL
Daily Signal:
Gain/Loss:
NTLA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

ABCL and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABCL has been loosely correlated with CRSP. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ABCL jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABCL
1D Price
Change %
ABCL100%
+9.53%
CRSP - ABCL
57%
Loosely correlated
N/A
RXRX - ABCL
57%
Loosely correlated
-3.92%
ABSI - ABCL
56%
Loosely correlated
+3.20%
VCYT - ABCL
56%
Loosely correlated
+2.63%
NTLA - ABCL
53%
Loosely correlated
+1.72%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
REX39.340.62
+1.60%
REX American Resources Corp
PC9.40N/A
N/A
Premium Catering Holdings Limited
ENB48.94-0.26
-0.53%
Enbridge
POWW2.34-0.08
-3.11%
Outdoor Holding Company
AN178.51-7.39
-3.98%
AutoNation